Clinical experiences with the use of oxytocin injection by healthcare providers in a southwestern state of Nigeria: A cross-sectional study
Chioma Stella Ejekam aff001; Ifeoma Peace Okafor aff002; Chimezie Anyakora aff003; Ebenezer A. Ozomata aff001; Kehinde Okunade aff004; Sofela Ezekiel Oridota aff001; Jude Nwokike aff003
Působiště autorů: Department of Community Health, Lagos University Teaching Hospital, Lagos, Nigeria aff001; Department of Community Health and Primary care, College of Medicine, University of Lagos, Akoka Lagos, Nigeria aff002; Promoting the Quality of Medicines Program, U.S. Pharmacopeial Convention, Rockville, Maryland, United States of America aff003; Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, Nigeria aff004
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
Postpartum hemorrhage (PPH) is a leading cause of maternal mortality in Nigeria and in most low- and middle-income countries. The World Health Organization (WHO) strongly recommends oxytocin as effective, affordable, and the safest drug of first choice in the prevention and treatment of PPH in the third stage of labor. However, there are concerns about its quality. Very high prevalence of poor-quality oxytocin, especially in Africa and Asia, has been reported in literature. Excessive and inappropriate use of oxytocin is also common in low-resource settings.
To assess clinical experiences with quality of oxytocin used by healthcare providers in Lagos State, Nigeria.
This was a descriptive cross-sectional study conducted in 2017, with 705 respondents (doctors and nurses) who use oxytocin for obstetrics and gynecological services recruited from 195 health facilities (public and registered private) across Lagos State. Data collection was quantitative, using a pretested self-administered questionnaire. Data analysis was performed with IBM SPSS version 21. Statistical significance was set at 5 percent (p<0.05). Ethical approval was obtained from Lagos University Teaching Hospital Health Research Ethics Committee.
Only 52 percent of the respondents knew oxytocin should be stored at 2°C to 8°C. About 80 percent of respondents used oxytocin for augmentation of labor, 68 percent for induction of labor, 51 percent for stimulation of labor, and 78 percent for management of PPH. Forty-one percent used 20IU and as much as 10% used 30IU to 60IU for management of PPH. About 13 percent of respondents reported believing they had used an ineffective brand of oxytocin in their practice. Just over a third (36%) had an available means of documenting or reporting perceived ineffectiveness of drugs in their facility; of these, only about 12 percent had pharmacovigilance forms in their facilities to report the ineffectiveness.
The inappropriate and inconsistent use of oxytocin, especially overdosing, likely led to the high perception of medicine effectiveness among respondents. This is coupled with lack of suspicion of medicine ineffectiveness by clinicians as a possible root cause of poor treatment response or disease progression. Poor knowledge of oxytocin storage and consequent poor storage practices could have contributed to the ineffectiveness reported by some respondents. It is necessary to establish a unified protocol for oxytocin use that is strictly complied with. Continuous training of healthcare providers in medicine safety monitoring is advocated.
Allied health care professionals – Health care facilities – Health care providers – Nigeria – Nurses – Obstetrics and gynecology – Oxytocin – Postpartum hemorrhage
1. Ezugwu EC, Agu PU, Nwoke MO, Ezugwu FO. Reducing maternal deaths in a low resource setting in Nigeria. Niger J Clin Pract. 2014;17(1):62–6. doi: 10.4103/1119-3077.122842 24326810
2. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012;1–41.
3. Filippi V, Chou D, Ronsmans C, Graham W, Say L. Levels and Causes of Maternal Mortality and Morbidity. In Black ER, Laxminarayan R, Temmerman M, Walker N, editors. Reprod Matern Newborn, Child Heal Dis Control Priorities Third Ed. 2016;2.
4. Pharmaceuticals Peckforton. Oxytocin 10 IU/ml Solution for infusion—Summary of Product Characteristics (SPC)—(eMC). Peckforton Pharmaceuticals. 2015. Available from: https://www.medicines.org.uk/emc/medicine/30427. Cited 2 November, 2017.
5. World Health Organization. WHO Recommendations for Augmentation of Labour. Geneva, Switzerland; 2014. pp. 1–64. Available from: https://www.ncbi.nlm.nih.gov/books/NBK258875/pdf/Bookshelf_NBK258875.pdf
6. Raifman S, Mellese S, Hailemariam K, Askew I, Erulkar A. Assessment of the availability and use of maternal health supplies in the primary health care system in Amhara Region, Ethiopia. Addis Ababa: Population Council. 2013. Available from: https://www.popcouncil.org/uploads/pdfs/2013RH_MaternalHealthSuppliesEthiopia.pdf. Cited 24 October, 2017.
7. Mullany LC, Newton S, Afari-Asiedu S, Adiibokah E, Agyemang CT, Cofie P, et al. Cumulative effects of heat exposure and storage conditions of Oxytocin-in-Uniject in rural Ghana: implications for scale up. Glob Heal Sci Pract. 2014;2(3):285–94.
8. Accelovate. How can we improve the quality of oxytocin? Baltimore, MD; 2015. Available from: www.jhpiego.org/accelovate. Cited 28 May, 2017.
9. Hall P. Quality of misoprostol and oxytocin products. Available from: https://www.rhsupplies.org/fileadmin/uploads/rhsc/General_Membership_Meetings/Mexico_2014/Presentations/Day_4/PS_Quality_-_Quality_of_maternal_health_drugs_and_emergency_contraception_-_Peter_Hall__Concept_Foundation.pdf. Cited 30 May, 2017.
10. Anyakora C, Oni Y, Ezedinachi U, Adekoya A, Ali I, Nwachukwu C, et al. Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits. BMC Pregnancy Childbirth. 2018;18(1):44. doi: 10.1186/s12884-018-1671-y 29382306
11. Torloni M, Freitas CG, Kartoglu U, Gulmezoglu A, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;(123):2076–86.
12. Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S. Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana. BMJ Open. 2012;2(3).
13. Gostin LO, Buckley GJ, editors. Countering the Problem of Falsified and Substandard Drugs. Washington, D.C.: National Academies Press; 2013. Available from: http://www.nap.edu/catalog/18272. Cited 30 May, 2017.
14. Fleurent A, Theunissen F, Vemer H. Quality Matters: Cheap Uterotonics—Bargain or Burden?—Concept Foundation. Available from: http://www.conceptfoundation.org/maternal-health/quality-matters-cheap-uterotonics-bargain-burden/. Cited 15 Jul, 2017.
15. Deepak NN, Mirzabagi E, Koski A, Tripathi V. Knowledge, Attitudes, and Practices Related to Uterotonic Drugs during Childbirth in Karnataka, India: A Qualitative Research Study. PLoS One. 2013;8(4):e62801. doi: 10.1371/journal.pone.0062801 23638148
16. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment of primary postpartum haemorrhage (Review). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD003249. doi: 10.1002/14651858.CD003249.pub3 24523225
17. Musa HA. Knowledge and use of Misoprostol in the prevention and treatment of postpartum haemorrhage among primary healthcare workers in Zaria Metropolis, Kaduna State, Nigeria. University of Nigeria, Nsukka. 2014. p. 1–70.
18. Tran DN, Bero LA. Barriers and facilitators to the quality use of essential medicines for maternal health in low–resource countries: An Ishikawa framework. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416332/pdf/jogh-05-010406.pdf. Cited 11 November, 2017.
19. Poudyal A, Shrestha B, Onta S. Availability and use of oxytocin in health facilities in Nepal. J Inst Med. 2014;36(1):3–8.
20. Lovold A, Stanton C. Use of oxytocin and misoprostol for induction or augmentation of labor in low-resource settings. Baltimore, Maryland. 2008. Available from: http://studylib.net/doc/7550912/use-of-oxytocin-and-misoprostol-for-induction-or. Cited 10 November, 2017.
21. World Health Organization. Survey of the quality of medicines identified by the United Nations Commission on Life-Saving Commodities for Women and Children. Geneva, Switzerland.; 2016.
22. Yaekob R, Shimelis T, Henok A, Lamaro T. Assessment Of Knowledge, Attitude, And Practice Of Midwives On Active Management Of Third Stage Of Labour At Selected Health Centers Of Addis Ababa, Ethiopia, 2014. J Biol. 2015;5(11):232–40.
23. University College London Hospitals (NHS Foundation). Guideline for the use of Oxytocin in Labour. 2009. Available from: http://www.uclhguide.com/fragr_image/media/oxytocin_labour. Cited 2 November, 2017.
24. WHO. WHO recommendation on the use of oxytocin alone for treatment of delay in labour. May 2014. pp. 1–5. Updated 2018. Available from: https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/care-during-childbirth/care-during-labour-1st-stage/who-recommendation-use-oxytocin-alone-treatment-delay-labour.
25. Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour. Cochrane Database Syst Rev. 2013. Available from: http://doi.wiley.com/10.1002/14651858.CD007123.pub3. Cited 6 June, 2019.
26. Oxytocin—National Library of Medicine HSDB Database. Available from: https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2182. Cited 3 June, 2019.
Článek vyšel v časopise
2019 Číslo 10
- Aktuální legislativní změny týkající se zdravotnických prostředků – přehledné shrnutí v kostce
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Do jaké míry chrání prodělání COVID-19 před těžkým průběhem reinfekce – výsledky metaanalýzy
- Českým pacientům je nově k dispozici extrakt léčebného konopí. Jaké benefity přináší?
- Není statin jako statin aneb praktický přehled rozdílů jednotlivých molekul